Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data
Nuvation Bio’s glioma drug has touted a 36-month progression-free survival (PFS) rate of 79% with nearly 40 months of follow-up, with its advancement to …
Post
-
-
European scientists advocate for integrative approach to obesity prevention
For decades, obesity has posed one of the most formidable threats to public health. Individuals living with obesity are at …
-
Inflammasome sets sights on Phase III amid eye disease drug’s mid-stage score
Inflammasome Therapeutics is eyeing a Phase III study for its geographic atrophy (GA) therapy, kamuvudine-8 (K8), after the drug significantly …
-
ThalassaX doses first US patient in Phase I study of CS231295
ThalassaX Therapeutics United States has dosed the first patient in its Phase I clinical trial of CS231295, a brain-penetrant Aurora …
-
Bayer and Henry Ford Health partner to boost clinical trial access
Bayer and Henry Ford Health have entered a strategic research partnership aimed at expanding access to clinical trials for patients. The …
-
J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
J&J EMEA Immunology therapeutic area head Mark Graham tells Srivani Venna that based on positive data from the Phase II …
-
GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid
GSK’s $2bn bid on Bellus Health has taken a knock, as the British pharma giant is terminating the late-stage refractory …
-
Trellis Bioscience secures Series C financing for TRL1068 trial
Trellis Bioscience has closed a $9m Series C funding round to support the completion of its ongoing Phase II clinical …
-
Takeda unveils secondary endpoint data from Phase III PsO pill trials
Takeda has released data for its plaque psoriasis (PsO) pill in key secondary endpoints in high-impact areas, supporting a route …
-
First patients dosed in Grifols Phase III immunoglobulin trials
Grifols has dosed the first patients in two separate Phase III trials designed to support the US label expansion of …
-
AAIC26: Roche charts expanded course for Alzheimer’s therapy, touts long-term anti-amyloid impact
Roche is eyeing a wider patient population for its anti-amyloid Alzheimer’s hopeful, trontinemab, as the space increasingly examines the potential …
-
MASH therapy enters a more competitive era
For much of the last two years, there has only been one real way to treat metabolic dysfunction-associated steatohepatitis (MASH). …
-
MediciNova achieves target enrolment in SEANOBI-ALS study of MN-166
MediciNova has achieved the target enrolment of 200 patients in the SEANOBI-ALS clinical study, evaluating MN-166 (ibudilast) for amyotrophic lateral …
-
Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other …
-
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Kairos Pharma has reported interim safety results from its ongoing Phase I clinical trial of ENV-105 (carotuximab), along with AstraZeneca's …
